Meet the Team
Senior Research Associate II, Discovery
Director, Project Management
Scientist II, Protein Sciences
Senior Research Associate, Discovery
Board Director
Dr. Gillis joined ARCH Venture Partners as a Venture Partner in 2005 and became a Managing Director in 2006. He is focused on the evaluation of new life science technologies and on the development and growth of ARCH’s biotechnology portfolio companies. He serves as a Director and/or Chairman of multiple companies within the ARCH ecosystem.
Dr. Gillis was a founder and director of Corixa Corporation and served as CEO from its inception and as its Chairman from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Dr. Gillis was a founder and director of Immunex Corporation. From 1981 until his departure in 1994, he served as Immunex’s Director of Research and Development, Chief Scientific Officer, and as CEO of Immunex’s R&D subsidiary. Dr. Gillis was interim CEO of Immunex Corp. following its majority purchase by American Cyanamid Co. and remained a member of the board until 1997. Amgen, Inc. acquired Immunex in 2002.
Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Dr. Gillis received a B.A. from Williams College and a Ph.D. from Dartmouth College.
Cofounder, Scientific Advisor, Board Observer
Board Director
Jacob Vogelstein is the Co-Founder & Managing Partner of Catalio Capital Management, LP. He is primarily responsible for managing the firm and for making investments in private breakthrough biomedical technology companies. He serves on the Investment Committee of Catalio’s flagship Nexus strategy and on the firmwide Management Committee.
Jacob currently serves on the Boards of Boost Neuroscience, Blackrock Neurotech, Cage Pharmaceuticals, Iambic Therapeutics, ManaT Bio, Nextpoint and Pheast Therapeutics.
Prior to founding Catalio, he was a General Partner at Camden Partners Holdings, LLC, a private equity firm that spun-out of T. Rowe Price, where he focused on making biomedical technology investments. Earlier in his career, Jacob served on the faculty at Johns Hopkins University, at both the Applied Physics Laboratory and the Whiting School of Engineering.
Jacob has received widespread recognition for his innovative work in biomedical engineering including the Presidential Early Career Award in Science and Engineering, which is the highest honor bestowed by the US Government on science and engineering professionals in the early stages of their careers.
Jacob earned his BSc. degree in Bio-Electrical Engineering from Brown University and his Ph.D. degree in Biomedical Engineering from the Johns Hopkins University School of Medicine.